A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in
patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).